Investors

Corporate Governance

Incanthera’s Board and management team possess a broad range of commercial, scientific and public company experience.

The Board comprises individuals who have all held long and distinguished positions within the healthcare and commercial industries.

CEO, Stuart Robertson’s strong history in investment and commercial activities, brings established company acquisition and IP experience, together with global manufacturing and commercial relationship strength, including as MD of Skin and Cell AG, to lead us in our commercialisation goals and onto the international stage.

CSO, Dr Simon Ward’s scientific and educational background, along with commercial experience provides the perfect platform to oversee his vision to transform the method and quality of technologies from laboratory to end user, that is the heart of Incanthera’s business.

We are fortunate to have had the long term support of Caroline Murray, as Non-Executive Director, whose large Pharma and cross- section of company experience, provides an invaluable sounding board of perception and wise counsel.

John Howes, as Non-Executive Director and Senior Independent Director brings first class corporate and City experience of over 40 years in UK equity capital markets, providing the Board with a solid support in his institutional relationship expertise and corporate guidance to further our commercial ambitions.

Our Key Senior Management team is diverse and skilled, providing every aspect we require to not only progress, but flourish. Their individual qualities have shown resilience, determination and the experience to fulfil our ambitions.

Laura Brogden, CFO, ensures our financial accounting, management and compliance obligations are fulfilled and met with ample time and poise.

Suzanne Brocks, Head of Communications and Company Secretary, oversees City, company and public facing communications, and oversees all shareholder information and compliance, ensuring both internally, and to the public, that we are delivering our message and maximising our opportunities, in line with regulations and governance.

These full spectrum qualities, ensure industry and commercial ambitions are met and opportunities and evolution are at the forefront of our strategic drive year after year. The team at Incanthera is the right one to deliver our own growth and commercialisation goals into future rewards to shareholders.

Stuart Robertson
Chief Executive Officer

CEO, Stuart Robertson has a strong history in investment and commercial activities, founding Swiss based global investment company GIFFRIES Technology AG in 2015, acquiring Énielle the subject of our acquisition and portfolio addition announced in June 2026.

Additionally, as founder and Managing Director of Skin and Cell AG in Switzerland since 2023, Stuart manages Incanthera’s manufacturing and commercial relationships in Switzerland and Europe as well as business introduction to commercial contacts globally. Prior to this he was employed at Accenture from 2007 to 2009, CK Hutchison and AS Watson Group from 2002 to 2007, ABB Group from 1997 to 2002 and EY from 1996 to 1997.

Mr Robertson graduated in 1989 from Queensland University of Technology with a BBA. He then completed a MEc Economics at Macquarie University in 1993 and qualified as a Chartered Accountant. He commenced his career at Arthur Andersen in Sydney in 1993 where he gained an MTax in 1995 from Sydney University’s Law School before joining ABB Asea Brown Boveri in Australia in 1997.

Dr Simon Ward
Chief Scientific Officer

Simon is a co-founder of Incanthera and has more than 30 years’ senior experience in academia and business.

He was a founder and CEO of Molecular SkinCare Limited, a pioneer and developer of novel dermatology products for the prevention and management of skin diseases. As CSO of York Pharma plc, he was responsible for bringing innovative dermatology product through to market. Simon also served as chairman of South Yorkshire Bioscience Enterprise Network (SYBEN) and deputy chairman of Medipex, a healthcare innovation hub for NHS organisations across industry and academia internationally.

Simon graduated from the University of London’s School of Pharmacy (UK) with a Joint Honours Degree in Pharmacology and Toxicology and was awarded a DPhil in the Department of Human Anatomy, Oxford University under a Glaxo Group Research Studentship.

John Howes
Senior Independent Director

With more than 43 years’ experience in UK equity capital markets, John brings a wealth of knowledge and Institutional relationships to Stanford Capital Partners. John has extensive experience in the UK equity capital markets building an established reputation in the small and mid-cap sectors, holding previous positions as Partner with Matrix Corporate Capital and senior positions at Seymour Pierce, Panmure Gordon, Northland Capital and Stanford Capital.

Caroline Murray
Non-Executive Director

Caroline’s expertise across healthcare, market positioning and strategic implementation brings extensive product management, and marketing and commercialisation experience to the Board. Senior positions held in the pharmaceutical industry, including both Novartis and Bristol Myers Squibb, over 30 years, combine dermatology, healthcare and commercial skills, perfectly suited to the company’s goals.

For the Company’s current formulation programme, Skin + CELL, the Company is working closely with two key individuals:

Professor Mike Cork

Working at the Sheffield Children’s Hospital and Sheffield Teaching Hospitals, Mike is a world-recognised opinion leader in disorders of the skin barrier and inventor of dermatological products. He runs a dedicated clinical research facility focused upon the response of normal and diseased skin to topical product.

Dr Kevin Hammond

Dr. Hammond has over 30 years’ experience working with some of the world’s leading Pharmaceutical, FMCG and Healthcare companies, where he has held responsibilities in directing new product innovation, partnering, licensing, and technology acquisition, for companies such as Reckitt Benckiser, Unilever, PZ Cussons, CB Fleet (US) and GSK. His experience includes operations in Europe, Latin America, North America, South East Asia and Central Asia.

In 2010, Dr. Hammond set up his own consultancy aimed at advising and working with SMEs and University spin-out companies seeking to commercialise their technologies in the Pharmaceutical, Healthcare and FMCG markets. Since this time, he has secured significant returns for clients through facilitating ‘entry’ into potential customer companies, partnering contracts, technology sales, and licensing and royalty agreements, including deals with companies such as P&G, GSK and Coty.